INT209865

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 0.15
Pain Relevance 0.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (CD36) transport (CD36) small molecule metabolic process (CD36)
cell adhesion (CD36) Golgi apparatus (CD36) plasma membrane (CD36)
CD36 (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 219 97.36 Very High Very High Very High
Inflammation 57 5.00 Very Low Very Low Very Low
rheumatoid arthritis 33 5.00 Very Low Very Low Very Low
cytokine 21 5.00 Very Low Very Low Very Low
aspirin 9 5.00 Very Low Very Low Very Low
dexamethasone 6 5.00 Very Low Very Low Very Low
Inflammatory response 6 5.00 Very Low Very Low Very Low
methotrexate 3 5.00 Very Low Very Low Very Low
cINOD 3 5.00 Very Low Very Low Very Low
metalloproteinase 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Repression 6 84.56 Quite High
Necrosis 12 50.00 Quite Low
Cancer 12 50.00 Quite Low
INFLAMMATION 66 5.00 Very Low Very Low Very Low
Increased Venous Pressure Under Development 36 5.00 Very Low Very Low Very Low
Rheumatoid Arthritis 33 5.00 Very Low Very Low Very Low
Disease 24 5.00 Very Low Very Low Very Low
Atherosclerosis 21 5.00 Very Low Very Low Very Low
Adhesions 12 5.00 Very Low Very Low Very Low
Obesity 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
and rosiglitazone inhibited the effect of the rosiglitazone by reducing CD36 mRNA expression (-59%, 0.41 ± 0.2, p = 0.002) in comparison to basal conditions.
Negative_regulation (reducing) of Transcription (expression) of CD36
1) Confidence 0.57 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.08 Pain Relevance 0
(10 ng/ml) reduced CD36 mRNA expression by 72% (mRNA relative level ± SD: 0.28 ± 0.05, p = 0.002), while adalimumab (1 ?
Negative_regulation (reduced) of Transcription (expression) of CD36 associated with adalimumab
2) Confidence 0.42 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0 Pain Relevance 0.32
reduced CD36 mRNA expression (-72%, 0.28 ± 0.05, p = 0.002), while rosiglitazone increased CD36 mRNA expression (+46%, 1.46 ± 0.2, p = 0.02).
Negative_regulation (reduced) of Transcription (expression) of CD36
3) Confidence 0.42 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.07 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox